| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H.;Lu Y.-S.;Chih-Hung Hsu;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; Yeh K.-H.; Lu Y.-S.; CHIH-HUNG HSU; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer
|
Shiah H.-S.;Cheng A.-L.;Hsu C.;Chih-Hung Hsu;Liu T.-W.;Chang J.-Y.;Jan C.-M.;Chao Y.;Yu W.-L.;Chuang T.-R.;Whang-Peng J.;Chen L.-T.; Shiah H.-S.; Cheng A.-L.; Hsu C.; CHIH-HUNG HSU; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2020-04-28T07:25:31Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
CHIH-HUNG HSU;Cheng A.-L.;Hsu W.-L.;Tsai Y.-C.;Hsu C.;Yang C.-H.;Yeh K.-H.;Lin C.-C.; Lin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; Cheng A.-L.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2020-04-28T07:25:30Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.; CHIH-HUNG HSU; Yu C.-J.; Chang Y.-C.; Hsu C.; Yang C.-H.;Yang P.-C.;Cheng A.-L.;Lin C.-C.;CHIH-HUNG HSU;Yu C.-J.;Chang Y.-C.;Hsu C.;Lin Z.-Z.; Lin Z.-Z. |
| 臺大學術典藏 |
2020-04-28T07:25:28Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.; Shen Y.-C.; CHIH-HUNG HSU; Chih-Hung Hsu;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Hsu C.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:28Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Chih-Hung Hsu;Yang T.-S.;Hsu C.;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; CHIH-HUNG HSU; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:27Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.;Lin Z.-Z.;Hsu C.;Shen Y.-C.;Chih-Hung Hsu;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:25Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
Yang S.-H. ;Kuo Y.-H. ;Tien Y.-W. ;Hsu C. ;Chih-Hung Hsu ;Kuo S.-H. ;Cheng A.-L.; Yang S.-H.; Kuo Y.-H.; Tien Y.-W.; Hsu C.; CHIH-HUNG HSU; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:25Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Hsu C. ;Shen Y.-C. ;Chih-Hung Hsu ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:14Z |
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
|
Yu C.-W.; Hsu C.-Y.; Chen B.-B.; Chen B.-B.;Hsu C.-Y.;Yu C.-W.;Liang P.-C.;Hsu C.;Chih-Hung Hsu;Cheng A.-L.;Shih T.T.-F.; Liang P.-C.; Hsu C.; CHIH-HUNG HSU; Cheng A.-L.; Shih T.T.-F. |
| 臺大學術典藏 |
2020-04-28T07:25:13Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Chih-Hung Hsu;Wang M.-J.;Cheng A.-L.;Hsu C.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; CHIH-HUNG HSU; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-28T07:25:08Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chih-Hung Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; CHIH-HUNG HSU; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2020-04-27T08:45:31Z |
Recent advances in non-surgical treatment for advanced hepatocellular carcinoma
|
Hsu C.;Chia-Hsien Cheng;Cheng A.-L.; Hsu C.; CHIA-HSIEN CHENG; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-27T08:45:13Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Seong J.; Jia J.-D.; Han K.-H.; Cheng A.-L.; Yeo W.; Hsu C.;Chen B.-B.;Chen C.-H.;Ho M.-C.;Chia-Hsien Cheng;Kokudo N.;Murakami T.;Yeo W.;Seong J.;Jia J.-D.;Han K.-H.;Cheng A.-L.; Hsu C.; Chen B.-B.; Chen C.-H.; Ho M.-C.; CHIA-HSIEN CHENG; Kokudo N.; Murakami T. |
| 臺大學術典藏 |
2020-04-27T08:45:07Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Huang Y.-H.; Lee K.-T.; Wang C.-C.; Chau G.-Y.; Lee W.-C.; Ting C.-T.; Lee P.-H.; Wu C.-C.; Huo T.-I.; Liao L.-Y.; Huang S.-F.; Hung C.-F.; Yang S.-S.; Chen R.-C.; Chen C.-H.; Dai C.-Y.; Wang T.-E.; Su C.-W.; Wang J.-H.; Lu S.-N.;Wang J.-H.;Su C.-W.;Wang T.-E.;Dai C.-Y.;Chen C.-H.;Chen R.-C.;Yang S.-S.;Hung C.-F.;Huang S.-F.;Liao L.-Y.;Huo T.-I.;Wu C.-C.;Lee P.-H.;Ting C.-T.;Lee W.-C.;Chau G.-Y.;Wang C.-C.;Lee K.-T.;Huang Y.-H.;Ho M.-C.;Lin S.-M.;Huang G.-T.;Chen K.-Y.;Lin X.-Z.;Hwang J.-I.;Chiou Y.-Y.;Wang C.-K.;Hu J.-T.;Chen S.-C.;Liang P.-C.;Lee R.-C.;Wu D.-K.;Lin C.-Y.;Lin C.-C.;Cheng A.-L.;Hsu C.;Chao Y.;Chen L.-T.;Wang P.-M.;Wang P.-M.;Hong J.-H.;Hsu H.-C.;Chen S.-W.;Leung S.W.;Chia-Hsien Cheng;Wu J.-C.;Wu C.-Y.;Hsu Y.-C.;Hsu C.-W.;Ni Y.-H.;Lin C.-L.;Local Ablation Group, Surveillance Group, Diagnosis Group, Staging Group, Surgery Group, Tace/Tare/Hai Group, Target Therapy/Systemic Therapy Group, Radiotherapy Group, Prevention Group, Drafting Group; Lu S.-N.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; CHIA-HSIEN CHENG; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2020-04-10T12:16:14Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.; Ding Y.-H.; YU-YUN SHAO; Chen P.-J.; Lin Z.-Z.; Shen Y.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:16:13Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:13Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
YU-YUN SHAO; Kuo K.-T.; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
YU-YUN SHAO; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:11Z |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; YU-YUN SHAO; Yeh Y.-C.; Lin Z.-Z.; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
YU-YUN SHAO; Lu L.-C.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer
|
Yeh K.-H.; Cheng A.-L.; Lin Y.-L.; Hsu C.; Cheng W.-F.; Hsu C.-H.; YU-YUN SHAO; Lu L.-C. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.; Cheng A.-L.; Jin K.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; YU-YUN SHAO; Su W.-C.; Sandoval-Tan J.; Chiou T.-J. |
| 臺大學術典藏 |
2020-04-10T12:16:08Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Hsu C.; YU-YUN SHAO; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Yu-Yun Shao;Hsu C.;Cheng W.-F.;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression
|
Hsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; YU-YUN SHAO; Cheng A.-L.; Ou D.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
YU-YUN SHAO; Chen B.-B.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Yu-Yun Shao;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; YU-YUN SHAO; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:55Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.;Yu-Yun Shao;Lu L.-C.;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; YU-YUN SHAO; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:54Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.; Yen C.-J.; Chao Y.; Lu L.-C.; Hsu C.; YU-YUN SHAO; Lu L.-C.;Hsu C.;Yu-Yun Shao;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:53Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Yu-Yun Shao;Liu T.-H.;Hsu C.;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-09T09:39:09Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y. Y.; Chen, B. B.; Ou, D. L.; Lin, Z. Z.; Hsu, C. H.; Wang, M. J.; Cheng, A. L.; Hsu, C. |
| 臺大學術典藏 |
2020-03-27T02:03:35Z |
Diagnostic value of 18F-FDG-PET/CT in indeterminate infiltrative hepatic lesions in an endemic area of viral hepatitis
|
Cheng M.-F.;Wu Y.-W.;Kao-Lang Liu;Yen R.-F.;Wu Y.-M.;Hsu C.;Chang Y.-T.;Tzen K.-Y.;Wang H.-P.; Cheng M.-F.; Wu Y.-W.; KAO-LANG LIU; Yen R.-F.; Wu Y.-M.; Hsu C.; Chang Y.-T.; Tzen K.-Y.; Wang H.-P. |
| 臺大學術典藏 |
2020-03-27T02:03:26Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
KAO-LANG LIU; Liang P.-C.; Chen C.-H.; Shih T.T.-F.; Hsu C.; Wu C.-H.; Shih I.-L.; Chen B.-B.; Chen B.-B.;Shih I.-L.;Wu C.-H.;Hsu C.;Chen C.-H.;Shih T.T.-F.;Kao-Lang Liu;Liang P.-C. |
| 臺大學術典藏 |
2020-03-27T02:03:25Z |
Cough with bile
|
Chang C.-C.; Hsu C.; KAO-LANG LIU |
| 臺大學術典藏 |
2020-03-25T03:28:06Z |
Grape seed proanthocyanidins protect cardiomyocytes from ischemia and reperfusion injury via Akt-NOS signaling
|
Vanden Hoek T.L.; Yuan C.-S.; Hamann K.J.; Sharp W.W.; WEI-TIEN CHANG; Qin Y.; Li C.-Q.; Mehendale S.R.; Hsu C.; Dossumbekova A.; Wojcik K.R.; Shao Z.-H.; Vanden Hoek T.L.;Yuan C.-S.;Hamann K.J.;WEI-TIEN CHANG;Sharp W.W.;Qin Y.;Li C.-Q.;Mehendale S.R.;Hsu C.;Dossumbekova A.;Wojcik K.R.;Shao Z.-H. |
| 臺大學術典藏 |
2020-03-24T04:02:55Z |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
Lin C.H.; Chen I.C.; Chen I.C. ;Lin C.H. ;Huang C.S. ;Lien H.C. ;Hsu C. ;Wen-Hung Kuo ;Lu Y.S. ;Cheng A.L.; Huang C.S.; Lien H.C.; Hsu C.; WEN-HUNG KUO; Lu Y.S.; Cheng A.L. |
| 臺大學術典藏 |
2020-03-23T07:19:36Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma
|
Hsu C.;Chiun-Sheng Huang;Chao T.-Y.;Lu Y.-S.;Bu C.-F.;Chen M.M.;Chang K.-J.;Cheng A.-L.; Hsu C.; CHIUN-SHENG HUANG; Chao T.-Y.; Lu Y.-S.; Bu C.-F.; Chen M.M.; Chang K.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-23T07:19:32Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Hsu C.; Yeh K.-H.; Wu C.-Y.; CHIUN-SHENG HUANG; Yang C.-H.; Lu Y.-S.; Hsu C.-H.; Cheng A.-L.; Lin C.-C. |
| 臺大學術典藏 |
2020-03-23T07:19:27Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Cheng A.-L.; Lin C.-H.; Chang K.-J.; Kuo W.-H.; Lee W.-C.; Hsu C.; CHIUN-SHENG HUANG; Liau J.-Y.; Lu Y.-S.; Shao Y.-Y.;Kuo K.-T.;Hu F.-C.;Lu Y.-S.;Chiun-Sheng Huang;Liau J.-Y.;Lee W.-C.;Hsu C.;Kuo W.-H.;Chang K.-J.;Lin C.-H.;Cheng A.-L.; Shao Y.-Y.; Kuo K.-T.; Hu F.-C. |
| 臺大學術典藏 |
2020-03-23T07:19:22Z |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
Cheng A.L.; Lu Y.S.; Kuo W.H.; Hsu C.; Lien H.C.; CHIUN-SHENG HUANG; Lin C.H.; Chen I.C.; Chen I.C.;Lin C.H.;Chiun-Sheng Huang;Lien H.C.;Hsu C.;Kuo W.H.;Lu Y.S.;Cheng A.L. |
| 臺大學術典藏 |
2020-03-23T04:00:47Z |
Wearable-based mobile health app in gastric cancer patients for postoperative physical activity monitoring: Focus group study
|
MING-TSAN LIN; Lai F.; Tsai C.J.; Hsu C.; Chang Y.-T.; Wu J.-M.;Ho T.-W.;Chang Y.-T.;Hsu C.;Tsai C.J.;Lai F.;Ming-Tsan Lin; Wu J.-M.; Ho T.-W. |
| 臺大學術典藏 |
2020-03-12T02:02:46Z |
Grape seed proanthocyanidins protect cardiomyocytes from ischemia and reperfusion injury via Akt-NOS signaling
|
Mehendale S.R.; Li C.-Q.; Qin Y.; Sharp W.W.; WEI-TIEN CHANG; Hamann K.J.; Yuan C.-S.; Vanden Hoek T.L.; Hsu C.; Wojcik K.R.; Dossumbekova A.; Shao Z.-H.; Vanden Hoek T.L.;Yuan C.-S.;Hamann K.J.;WEI-TIEN CHANG;Sharp W.W.;Qin Y.;Li C.-Q.;Mehendale S.R.;Hsu C.;Dossumbekova A.;Wojcik K.R.;Shao Z.-H. |
| 臺大學術典藏 |
2020-03-07T06:42:17Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Shao Y.-Y.;Kuan-Ting Kuo;Hu F.-C.;Lu Y.-S.;Huang C.-S.;Liau J.-Y.;Lee W.-C.;Hsu C.;Kuo W.-H.;Chang K.-J.;Lin C.-H.;Cheng A.-L.; Shao Y.-Y.; KUAN-TING KUO; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-03-07T06:42:06Z |
Epithelioid Trophoblastic Tumor Around an Abdominal Cesarean Scar: A Pathologic and Molecular Genetic Analysis
|
Hsiue E.H.-C.;Hsu C.;Tseng L.-H.;Lu T.-P.;Kuan-Ting Kuo; Hsiue E.H.-C.; Hsu C.; Tseng L.-H.; Lu T.-P.; KUAN-TING KUO |
| 臺大學術典藏 |
2020-03-06T08:25:33Z |
Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate
|
Lin C.-H.;Yen R.-F.;Yung-Ming Jeng;Tzen C.-Y.;Hsu C.;Hong R.-L.; Lin C.-H.; Yen R.-F.; YUNG-MING JENG; Tzen C.-Y.; Hsu C.; Hong R.-L. |
| 臺大學術典藏 |
2020-03-06T08:25:32Z |
CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma
|
Su M.-C.;Hsu C.;Kao H.-L.;Yung-Ming Jeng; Su M.-C.; Hsu C.; Kao H.-L.; YUNG-MING JENG |
| 臺大學術典藏 |
2020-03-06T08:25:30Z |
Expression of the caudal-type homeodomain transcription factor CDX2 is related to clinical outcome in biliary tract carcinoma
|
Chang Y.-T.;Hsu C.;Yung-Ming Jeng;Chang M.-C.;Wei S.-C.;Wong J.-M.; Chang Y.-T.; Hsu C.; YUNG-MING JENG; Chang M.-C.; Wei S.-C.; Wong J.-M. |
| 臺大學術典藏 |
2020-03-06T08:25:25Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Shen Y.-C.; Hu F.-C.; YUNG-MING JENG; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; Hsu C.; Cheng A.-L. |
